Evidence map›Paper›PMID 42444701›Full record

ArticleRSC advances2026

Discovery of novel anti-

Ahmed Sabt, Veronika Furlan, Aladdin M Srour, Maciej Chyb, Hanaa Farag, Asmaa Saleh, Yusuke Kasai, Hiroshi Imagawa, Justyna Gatkowska, Abdelsamed I Elshamy and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ahmed SabtChemistry of Natural Compounds Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre Dokki Cairo 12622 Egypt sabt.nrc@gmail.com.ORCID https://orcid.org/0000-0001-6976-0196
Veronika FurlanFaculty of Chemistry and Chemical Engineering, University of Maribor Smetanova 17 SI-2000 Maribor Slovenia.
Aladdin M SrourDepartment of Therapeutic Chemistry, National Research Centre Dokki Cairo 12622 Egypt.ORCID https://orcid.org/0000-0002-6692-6952
Maciej ChybDepartment of Molecular Microbiology, Faculty of Biology and Environmental Protection, University of Lodz Banacha 12/16 90-237 Lodz Poland.
Hanaa FaragPesticide Chemistry Department, Chemical Industries Research Institute, National Research Centre Cairo 12622 Egypt.ORCID https://orcid.org/0000-0002-5666-3765
Asmaa SalehDepartment of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdulrahman University P.O. Box 84428 Riyadh 11671 Saudi Arabia.ORCID https://orcid.org/0000-0002-6286-319X
Yusuke KasaiFaculty of Pharmaceutical Sciences, Tokushima Bunri University Yamashiro-cho Tokushima Japan.
Hiroshi ImagawaFaculty of Pharmaceutical Sciences, Tokushima Bunri University Yamashiro-cho Tokushima Japan.
Justyna GatkowskaDepartment of Molecular Microbiology, Faculty of Biology and Environmental Protection, University of Lodz Banacha 12/16 90-237 Lodz Poland.
Abdelsamed I ElshamyChemistry of Natural Compounds Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre Dokki Cairo 12622 Egypt sabt.nrc@gmail.com.ORCID https://orcid.org/0000-0003-3302-3623
Jarosław DziadekLaboratory of Genetics and Physiology of Mycobacterium, Institute of Medical Biology of the Polish Academy of Sciences Lodz Poland jdziadek@cbm.pan.pl.ORCID https://orcid.org/0000-0003-1427-884X
Urban BrenFaculty of Chemistry and Chemical Engineering, University of Maribor Smetanova 17 SI-2000 Maribor Slovenia.
Wagdy M EldehnaDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University Kafr El Sheikh 33516 Egypt wagdy2000@gmail.com.ORCID https://orcid.org/0000-0001-6996-4017

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toxoplasmosis is a globally prevalent parasitic infection that disproportionately impacts immunocompromised individuals and remains a significant public health challenge. The limitations of current standard-of-care therapies, marked by severe adverse effects and an inability to eradicate persistent cysts, necessitate the urgent development of novel, safer, and more efficacious anti-

Identifiers

PMID42444701
PMCPMC13358707

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.